Cargando…

Progression risk stratification with six-minute walk gait speed trajectory in multiple sclerosis

BACKGROUND: Multiple Sclerosis (MS) disease progression has notable heterogeneity among patients and over time. There is no available single method to predict the risk of progression, which represents a significant and unmet need in MS. METHODS: MS and healthy control (HC) participants were recruite...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldman, Myla D., Chen, Shanshan, Motl, Robert, Pearsall, Rylan, Oh, Unsong, Brenton, J. Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582752/
https://www.ncbi.nlm.nih.gov/pubmed/37859654
http://dx.doi.org/10.3389/fneur.2023.1259413
_version_ 1785122402230861824
author Goldman, Myla D.
Chen, Shanshan
Motl, Robert
Pearsall, Rylan
Oh, Unsong
Brenton, J. Nicholas
author_facet Goldman, Myla D.
Chen, Shanshan
Motl, Robert
Pearsall, Rylan
Oh, Unsong
Brenton, J. Nicholas
author_sort Goldman, Myla D.
collection PubMed
description BACKGROUND: Multiple Sclerosis (MS) disease progression has notable heterogeneity among patients and over time. There is no available single method to predict the risk of progression, which represents a significant and unmet need in MS. METHODS: MS and healthy control (HC) participants were recruited for a 2-year observational study. A latent-variable growth mixture model (GMM) was applied to cluster baseline 6-min walk gait speed trajectories (6MW(GST)). MS patients within different 6 MW(GST) clusters were identified and stratified. The group membership of these MS patients was compared against 2-year confirmed-disease progression (CDP). Clinical and patient-reported outcome (PRO) measures were compared between HC and MS subgroups over 2 years. RESULTS: 62 MS and 41 HC participants completed the 2-year study. Within the MS cohort, 90% were relapsing MS. Two distinct patterns of baseline 6 MW(GST) emerged, with one cluster displaying a faster gait speed and a typical “U” shape, and the other showing a slower gait speed and a “flattened” 6 MW(GST) curve. We stratified MS participants in each cluster as low- and high-risk progressors (LRP and HRP, respectively). When compared against 2-year CDP, our 6 MW(GST) approach had 71% accuracy and 60% positive predictive value. Compared to the LRP group, those MS participants stratified as HRP (15 out of 62 MS participants), were on average 3.8 years older, had longer MS disease duration and poorer baseline performance on clinical outcomes and PROs scores. Over the subsequent 2 years, only the HRP subgroup showed a significant worsened performance on 6 MW, clinical measures and PROs from baseline. CONCLUSION: Baseline 6 MW(GST) was useful for stratifying MS participants with high or low risks for progression over the subsequent 2 years. Findings represent the first reported single measure to predict MS disease progression with important potential applications in both clinical trials and care in MS.
format Online
Article
Text
id pubmed-10582752
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105827522023-10-19 Progression risk stratification with six-minute walk gait speed trajectory in multiple sclerosis Goldman, Myla D. Chen, Shanshan Motl, Robert Pearsall, Rylan Oh, Unsong Brenton, J. Nicholas Front Neurol Neurology BACKGROUND: Multiple Sclerosis (MS) disease progression has notable heterogeneity among patients and over time. There is no available single method to predict the risk of progression, which represents a significant and unmet need in MS. METHODS: MS and healthy control (HC) participants were recruited for a 2-year observational study. A latent-variable growth mixture model (GMM) was applied to cluster baseline 6-min walk gait speed trajectories (6MW(GST)). MS patients within different 6 MW(GST) clusters were identified and stratified. The group membership of these MS patients was compared against 2-year confirmed-disease progression (CDP). Clinical and patient-reported outcome (PRO) measures were compared between HC and MS subgroups over 2 years. RESULTS: 62 MS and 41 HC participants completed the 2-year study. Within the MS cohort, 90% were relapsing MS. Two distinct patterns of baseline 6 MW(GST) emerged, with one cluster displaying a faster gait speed and a typical “U” shape, and the other showing a slower gait speed and a “flattened” 6 MW(GST) curve. We stratified MS participants in each cluster as low- and high-risk progressors (LRP and HRP, respectively). When compared against 2-year CDP, our 6 MW(GST) approach had 71% accuracy and 60% positive predictive value. Compared to the LRP group, those MS participants stratified as HRP (15 out of 62 MS participants), were on average 3.8 years older, had longer MS disease duration and poorer baseline performance on clinical outcomes and PROs scores. Over the subsequent 2 years, only the HRP subgroup showed a significant worsened performance on 6 MW, clinical measures and PROs from baseline. CONCLUSION: Baseline 6 MW(GST) was useful for stratifying MS participants with high or low risks for progression over the subsequent 2 years. Findings represent the first reported single measure to predict MS disease progression with important potential applications in both clinical trials and care in MS. Frontiers Media S.A. 2023-10-04 /pmc/articles/PMC10582752/ /pubmed/37859654 http://dx.doi.org/10.3389/fneur.2023.1259413 Text en Copyright © 2023 Goldman, Chen, Motl, Pearsall, Oh and Brenton. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Goldman, Myla D.
Chen, Shanshan
Motl, Robert
Pearsall, Rylan
Oh, Unsong
Brenton, J. Nicholas
Progression risk stratification with six-minute walk gait speed trajectory in multiple sclerosis
title Progression risk stratification with six-minute walk gait speed trajectory in multiple sclerosis
title_full Progression risk stratification with six-minute walk gait speed trajectory in multiple sclerosis
title_fullStr Progression risk stratification with six-minute walk gait speed trajectory in multiple sclerosis
title_full_unstemmed Progression risk stratification with six-minute walk gait speed trajectory in multiple sclerosis
title_short Progression risk stratification with six-minute walk gait speed trajectory in multiple sclerosis
title_sort progression risk stratification with six-minute walk gait speed trajectory in multiple sclerosis
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582752/
https://www.ncbi.nlm.nih.gov/pubmed/37859654
http://dx.doi.org/10.3389/fneur.2023.1259413
work_keys_str_mv AT goldmanmylad progressionriskstratificationwithsixminutewalkgaitspeedtrajectoryinmultiplesclerosis
AT chenshanshan progressionriskstratificationwithsixminutewalkgaitspeedtrajectoryinmultiplesclerosis
AT motlrobert progressionriskstratificationwithsixminutewalkgaitspeedtrajectoryinmultiplesclerosis
AT pearsallrylan progressionriskstratificationwithsixminutewalkgaitspeedtrajectoryinmultiplesclerosis
AT ohunsong progressionriskstratificationwithsixminutewalkgaitspeedtrajectoryinmultiplesclerosis
AT brentonjnicholas progressionriskstratificationwithsixminutewalkgaitspeedtrajectoryinmultiplesclerosis